Winkelmann Ria, Weißgerber Maja, Wild Peter J, Bein Julia, Fleischmann Maximilian, Demes Melanie, Balermpas Panagiotis, Loth Andreas, Bankov Katrin, von der Grün Jens
Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
Frankfurt Institute for Advanced Studies (FIAS), Ruth-Moufang-Straße 1, 60438 Frankfurt am Main, Germany.
Life (Basel). 2024 Aug 29;14(9):1089. doi: 10.3390/life14091089.
Salivary gland cancer (SGC) is a rare cancer that can present a diagnostic challenge to pathologists, with emerging, but still limited options for the treatment of recurrent/metastatic disease. We aimed to characterize the cohort of salivary gland cancers in our institute and generate a tissue microarray (TMA) with clinical data available for immunohistochemical analysis. We extracted the cases of salivary gland cancers in our institute and generated a TMA with 72 patients between 2002 and 2017 with sufficient paraffin block material. Follow-up data were present for all cases. The TMA was stained with three p53 antibodies as well as MSH2, MSH6, PMS2 and MLH1 antibodies. Additionally, we applied fragment analysis based on the Bethesda panel, and the IdyllaTM MSI test to cases with expression loss of any of the mismatch repair proteins (MMR-P) according to our immunohistochemistry (IHC). The investigated cohort shows that pT and pN stage are the only factors independently associated with survival, according to our multivariate analysis ( = 0.037 and = 0.014). In univariate analysis, risk factors identified in our cohort were also age ( = 0.015), (lympho-) vascular invasion ( = 0.002 and = 0.003) and risk stratification ( = 0.037). The p53 protein investigated by three antibodies showed no statistically significant association with survival or other tumor characteristics in the investigated cohort. According to MMR-P IHC, six cases of SGC showed an aberrant IHC phenotype. Additional IdyllaTM MSI test and fragment length analysis failed to confirm microsatellite instability. The pT and pN stage are the most important factors for survival in our cohort. In our cohort, antibodies directed against the protein p53 did not contribute to clinical decision-making and were not correlated with any known clinical characteristics. MSI appears to be insignificant in SGCs. Larger cohorts are needed for verification.
涎腺癌(SGC)是一种罕见癌症,对病理学家来说在诊断方面具有挑战性,对于复发/转移性疾病的治疗,虽有新出现但仍有限的选择。我们旨在对本研究所的涎腺癌队列进行特征描述,并制作一个带有可用于免疫组织化学分析的临床数据的组织微阵列(TMA)。我们提取了本研究所的涎腺癌病例,并在2002年至2017年间为72例有足够石蜡块材料的患者制作了一个TMA。所有病例均有随访数据。该TMA用三种p53抗体以及MSH2、MSH6、PMS2和MLH1抗体进行染色。此外,根据我们的免疫组织化学(IHC)结果,对于任何错配修复蛋白(MMR-P)表达缺失的病例,我们应用了基于贝塞斯达检测板的片段分析以及IdyllaTM MSI检测。根据我们的多变量分析(P = 0.037和P = 0.014),研究队列显示pT和pN分期是仅有的与生存独立相关的因素。在单变量分析中,我们队列中确定的风险因素还有年龄(P = 0.015)、(淋巴)血管侵犯(P = 0.002和P = 0.003)以及风险分层(P = 0.037)。用三种抗体检测的p53蛋白在研究队列中与生存或其他肿瘤特征无统计学显著关联。根据MMR-P IHC,6例SGC显示出异常的IHC表型。额外的IdyllaTM MSI检测和片段长度分析未能证实微卫星不稳定性。pT和pN分期是我们队列中生存的最重要因素。在我们的队列中,针对p53蛋白的抗体对临床决策没有帮助,且与任何已知临床特征均无关联。微卫星不稳定性在SGC中似乎不显著。需要更大的队列进行验证。